Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025BloodOpen Access

Erythrocyte membrane-camouflaged JAK1 inhibitor for the treatment of hemophagocytic lymphohistiocytosis

View Full Paper
Ask AI
Bookmark
Share

Authors

YWYu Wu

Discussion

Loading...

Member takes

Overview

Preclinical findings demonstrate that erythrocyte-membrane-camouflaged JAK1 inhibitors reduce splenomegaly and macrophage activation in HLH, suggesting a new treatment approach.

Key Points

  • To evaluate the efficacy of erythrocyte membrane-camouflaged JAK1 inhibitors in treating hemophagocytic lymphohistiocytosis (HLH).
  • Established HLH in mice using CpG-ODN injection.
  • Treated mice with Golidocitinib and Ruxolitinib.
  • Engineered and evaluated erythrocyte membrane-camouflaged JAK1 inhibitors in an HLH murine model.
  • Performed flow cytometric analysis of splenocytes for immune profiling.
  • DZD treatment reduced splenomegaly significantly compared to Ruxolitinib.
  • Increased erythrocyte and leukocyte counts in the DZD treated group.
  • Engineered mn@DZD nanoparticles showed effective encapsulation and therapeutic effect in HLH model.
  • mn@DZD treatment led to stable body weight maintenance and reduced inflammation indicators.

Cite This Study

Yu Wu (2025) studied this question.

synapsesocial.com/papers/69362f514fa91c937236d9a7https://doi.org/10.1182/blood-2025-2991
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Dual anti-HLH and antitumor efficacy of golidocitinib in relapsed/refractory PTCL-associated hemophagocytic lymphohistiocytosis: A retrospective safety and activity analysis2025
  2. 2Efficacy and mechanism of BTK degrader nx-5948 in secondary hemophagocytic lymphohistiocytosis2025
  3. 3OA12 JAK inhibitors, an emerging therapeutic target in haemophagocytic lymphohistiocytosis: results from a service evaluation of the UK HLH MDT2026
  4. 4Ruxolitinib Penetrates Blood Brain Barrier and Reduces the Cytokine Storm in Patients With Haemophagocytic Lymphohistiocytosis2026
  5. 5HLH-JAK, the first OPEN-label, phase II study evaluating ANTI-JAK1 itacitinib, for NON severe HLH in adults.2025